Interesting AMLX Put And Call Options For September 18th

Amylyx Pharmaceuticals (AMLX) option strategies presented: a $15.00 put trading with a $3.20 bid would net a $11.80 effective cost basis (stock at $15.55), is ~4% out-of-the-money, has a ~70% probability of expiring worthless and would yield 21.33% (33.28% annualized) on cash commitment if it does. On the call side, a $16.00 call with a $3.60 bid used as a covered-call against shares bought at $15.55 would deliver a 26.05% total return if called at the September 18 expiration, with a 32% chance of expiring worthless and a 23.15% premium boost (36.12% annualized). Implied volatility for both contracts is ~121% versus a trailing 12-month volatility of 74%.

Analysis

Market structure: Short-dated option sellers and yield-seeking retail/institutional accounts are the clear winners — the market is offering 21–36% annualized YieldBoosts (21.33% for the $15 put, 23.15% for the $16 call) because implied vol (≈121%) is ~65% higher than realized (74%). AMLX equity holders are exposed to assignment risk and upside-capping from covered-call desks; biotech peers may see correlated flows if hedges/assignments force block selling. Cross-asset effects are localized: large option hedging flows could amplify small-cap biotech idiosyncratic moves, modestly raise equity-basis financing needs and briefly pressure credit spreads for small biotech issuers.

Risk assessment: Tail risks are classical biotech binaries — negative Phase/clinical readouts, adverse FDA news, or a cash-raise/dilution that would drop shares >30–50% in days; counterparty/assignment risk creates operational funding needs if puts are assigned. Timeline: immediate (days) — option-gamma and assignment risk; short-term (weeks–months) — trial readouts/cash runway; long-term (quarters+) — fundamental clinical progress and commercialization. Hidden deps: many sellers are retail/covered-call ETFs; forced selling around expiration can exaggerate moves; IV re-pricing is the main second-order risk.

Trade implications: Given IV>realized, favour defined-risk premium-selling: sell-to-open AMLX $15 puts (collect ≥$3.20) or sell $15/$12.50 put spreads to cap downside; buy-write AMLX + sell $16 calls to lock 26% to-expiry return if comfortable capping upside. Position sizing: keep individual AMLX exposure small (1–3% portfolio) and use spreads to limit assignment capital demand; avoid naked straddles or uncovered short-delta positions.

Contrarian angles: Consensus focuses on yield but underestimates binary downside — implied vol underwrites a high probability of big moves which can blow up short-premium trades if a negative catalyst hits. Historical parallel: small-cap biotech often rewards disciplined short-vol sellers until a binary event; therefore the mispricing is real but conditional — sell premium only with strict width/roll rules. Unintended consequence: heavy net selling could invite opportunistic buyers to accumulate shares post-dilution, creating asymmetric recovery; set stop/roll rules accordingly.

Key Decisions for Investors

• Sell-to-open AMLX Sep 18 $15 put for net credit ≥ $3.20 (target collected premium); size ≤ 1–2% portfolio notional, effective purchase basis if assigned = $11.80/share; buy-to-close or roll if premium doubles or if AMLX < $12.50 before expiration.
• Establish buy-write: purchase AMLX up to 1–3% portfolio at current market (~$15.55) and sell-to-open Sep 18 $16 call for ≥ $3.60, target total return ~26% to expiry; if stock > $18 pre-expiration, take profits or roll up-and-out.
• Prefer defined-risk put spread instead of naked put: sell Sep 18 $15 / buy $12.50 put to limit assignment capital — only execute if spread net credit ≥ $1.80; max loss = $2.50 - credit. Size ≤ 2% portfolio.
• Relative-value hedge: if initiating above trades, short 0.5–1.0% portfolio notional of XBI (or IBB) to hedge sector beta — reduce exposure if IV compresses to <90% or if AMLX shows positive clinical readout.
• Monitor (actionable triggers): 1) IV level — close/trim short-premium positions if AMLX IV >200%; 2) corporate filings — avoid assignment/roll during any announced secondary offering within 30–60 days; 3) clinical/FDA calendar — tighten stops 7 trading days before any readout.